Related Experiment Video

Updated: May 24, 2026

Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells
07:12

Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells

Published on: September 9, 2021

Targeting the interleukin-6/Jak/stat pathway in human malignancies

Pasquale Sansone1, Jacqueline Bromberg

  • 1Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, NY 10021, USA.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|February 23, 2012
PubMed

Insights

The Janus kinase/signal transducer and activator of transcription (Jak/Stat) pathway, particularly interleukin-6-mediated Stat3 activation, is crucial in cancer development and progression. Inhibitors targeting this pathway show promise for cancer treatment.

Area of Science:

  • Molecular Biology
  • Oncology
  • Cell Signaling

Background:

  • The Janus kinase/signal transducer and activator of transcription (Jak/Stat) pathway mediates cytokine signaling.
  • Over 2,500 articles highlight its role in malignancies.
  • Interleukin-6 (IL-6)-mediated activation of Stat3 is a key pathway in tumorigenesis.

Purpose of the Study:

  • To review the Jak/Stat pathway's role in nonmalignant and malignant conditions.
  • To explore the influence of other Stats.
  • To discuss Jak/Stat inhibitors for cancer therapy.

Main Methods:

  • Literature review of published articles on the Jak/Stat pathway.
  • Analysis of the role of Stat3 activation in cancer.
  • Examination of current and potential Jak/Stat inhibitors.

Main Results:

  • Stat3 regulates critical mediators of tumor formation and metastasis.
  • The pathway is implicated in both tumor-intrinsic and extrinsic processes.
  • IL-6/Stat3 signaling is a principal driver of tumorigenesis.

Conclusions:

  • The Jak/Stat pathway, especially IL-6/Stat3, is vital in cancer.
  • Understanding this pathway is key to developing targeted therapies.
  • Jak/Stat inhibitors offer potential for cancer control and eradication.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...